The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage

Experimental Cell Research

Volumn 330, Issue 1, 2015, Pages 199-211

  Wang, Xuening ^a   Pesakhov, Stella ^b   Harrison, Jonathan S ^c   Kafka, Michael ^b   Danilenko, Michael ^b   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Robert Wood Johnson Medical School   (United States)

Author keywords

AML; ERK1 2; ERK5; M CSFR; MAPK; Vitamin D

Indexed keywords

CALCITRIOL; COLONY STIMULATING FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; COLONY STIMULATING FACTOR RECEPTOR; MAPK1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; EX VIVO STUDY; HL 60 CELL LINE; HUMAN; HUMAN CELL; MACROPHAGE FUNCTION; MONOCYTE; PHAGOCYTOSIS; PHENOTYPE; PROTEIN EXPRESSION; U937 CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM;

CELL DIFFERENTIATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 7; PHENOTYPE; PROTEIN KINASE INHIBITORS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; U937 CELLS;

EID: 84916937190     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.10.003     Document Type: Article

References (63)

1. Ridge S.A., Worwood M., Oscier D., Jacobs A., Padua R.A. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1377-1380.
2. Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N., Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M., Adamson J., Kouri N., Sundal C., Shuster E.A., Aasly J., MacKenzie J., Roeber S., Kretzschmar H.A., Boeve B.F., Knopman D.S., Petersen R.C., Cairns N.J., Ghetti B., Spina S., Garbern J., Tselis A.C., Uitti R., Das P., Van Gerpen J.A., Meschia J.F., Levy S., Broderick D.F., Graff-Radford N., Ross O.A., Miller B.B., Swerdlow R.H., Dickson D.W., Wszolek Z.K. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 2012, 44:200-205.
3. Barreda D.R., Hanington P.C., Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. 2004, 28:509-554.
4. Hamilton J.A., Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 2013, 34:81-89.
5. Broughton S.E., Hercus T.R., Lopez A.F., Parker M.W. Cytokine receptor activation at the cell surface. Curr. Opin. Struct. Biol. 2012, 22:350-359.
6. Mouchemore K.A., Pixley F.J. CSF-1 signaling in macrophages: pleiotrophy through phosphotyrosine-based signaling pathways. Crit. Rev. Clin. Lab. Sci. 2012, 49:49-61.
7. Hercus T.R., Broughton S.E., Ekert P.G., Ramshaw H.S., Perugini M., Grimbaldeston M., Woodcock J.M., Thomas D., Pitson S., Hughes T., D'Andrea R.J., Parker M.W., Lopez A.F. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors 2012, 30:63-75.
8. Liongue C., Wright C., Russell A.P., Ward A.C. Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. Int. J. Biochem. Cell Biol. 2009, 41:2372-2375.
9. Broughton S.E., Dhagat U., Hercus T.R., Nero T.L., Grimbaldeston M.A., Bonder C.S., Lopez A.F., Parker M.W. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol. Rev. 2012, 250:277-302.
10. Bourette R.P., Rohrschneider L.R. Early events in M-CSF receptor signaling. Growth Factors 2000, 17:155-166.
11. Suzu S., Hiyoshi M., Yoshidomi Y., Harada H., Takeya M., Kimura F., Motoyoshi K., Okada S. M-CSF-mediated macrophage differentiation but not proliferation is correlated with increased and prolonged ERK activation. J. Cell Physiol. 2007, 212:519-525.
12. Douglass T.G., Driggers L., Zhang J.G., Hoa N., Delgado C., Williams C.C., Dan Q., Sanchez R., Jeffes E.W., Wepsic H.T., Myers M.P., Koths K., Jadus M.R. Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies. Int. Immunopharmacol. 2008, 8:1354-1376.
13. Liu Y., Jenkins B., Shin J.L., Rohrschneider L.R. Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase. Mol. Cell Biol. 2001, 21:3047-3056.
14. Novak U., Harpur A.G., Paradiso L., Kanagasundaram V., Jaworowski A., Wilks A.F., Hamilton J.A. Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 1995, 86:2948-2956.
15. Balmanno K., Cook S.J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16:368-377.
16. Meloche S., Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26:3227-3239.
17. Nishimoto S., Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006, 7:782-786.
18. Deschenes-Simard X., Kottakis F., Meloche S., Ferbeyre G. ERKs in cancer: friends or foes?. Cancer Res. 2014, 74:412-419.
19. Wang X., Merritt A.J., Seyfried J., Guo C., Papadakis E.S., Finegan K.G., Kayahara M., Dixon J., Boot-Handford R.P., Cartwright E.J., Mayer U., Tournier C. Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol. Cell Biol. 2005, 25:336-345.
20. Obara Y., Yamauchi A., Takehara S., Nemoto W., Takahashi M., Stork P.J., Nakahata N. ERK5 activity is required for nerve growth factor-induced neurite outgrowth and stabilization of tyrosine hydroxylase in PC12 cells. J. Biol. Chem. 2009, 284:23564-23573.
21. Pan Y.W., Zou J., Wang W., Sakagami H., Garelick M.G., Abel G., Kuo C.T., Storm D.R., Xia Z. Inducible and conditional deletion of extracellular signal-regulated kinase 5 disrupts adult hippocampal neurogenesis. J. Biol. Chem. 2012, 287:23306-23317.
22. Wang W., Pan Y.W., Wietecha T., Zou J., Abel G.M., Kuo C.T., Xia Z. Extracellular signal-regulated kinase 5 (ERK5) mediates prolactin-stimulated adult neurogenesis in the subventricular zone and olfactory bulb. J. Biol. Chem. 2013, 288:2623-2631.
23. Wang W., Pan Y.W., Zou J., Li T., Abel G.M., Palmiter R.D., Storm D.R., Xia Z. Genetic activation of ERK5 MAP kinase enhances adult neurogenesis and extends hippocampus-dependent long-term memory. J. Neurosci. 2014, 34:2130-2147.
24. Rovida E., Spinelli E., Sdelci S., Barbetti V., Morandi A., Giuntoli S., Sbarba P.Dello ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. J. Immunol. 2008, 180:4166-4172.
25. Charni S., de Bettignies G., Rathore M.G., Aguilo J.I., van den Elsen P.J., Haouzi D., Hipskind R.A., Enriquez J.A., Sanchez-Beato M., Pardo J., Anel A., Villalba M. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J. Immunol. 2010, 185:3498-3503.
26. 3. Cell Cycle 2010, 9:4542-4551.
27. Wang X., Pesakhov S., Harrison J.S., Danilenko M., Studzinski G.P. ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells. J. Cell Physiol. 2014, 229:856-867.
28. 2 vitamin D-induced terminal differentiation of myeloid leukemia cells. J. Steroid Biochem. Mol. Biol. 2013.
29. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., Metzgar R., Aulakh G., Ting R., Ruscetti F., Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979, 54:713-733.
30. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 1976, 17:565-577.
31. Garner C.M., Hubbold L.M., Chakraborti P.R. Mycoplasma detection in cell cultures: a comparison of four methods. Br. J. Biomed. Sci. 2000, 57:295-301.
32. 3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol. Oncol. 2010, 28:124-132.
33. Liel Y., Rudich A., Nagauker-Shriker O., Yermiyahu T., Levy R. Monocyte dysfunction in patients with Gaucher disease: evidence for interference of glucocerebroside with superoxide generation. Blood 1994, 83:2646-2653.
34. Kim K.B., Kefford R., Pavlick A.C., Infante J.R., Ribas A., Sosman J.A., Fecher L.A., Millward M., McArthur G.A., Hwu P., Gonzalez R., Ott P.A., Long G.V., Gardner O.S., Ouellet D., Xu Y., DeMarini D.J., Le N.T., Patel K., Lewis K.D. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 2013, 31:482-489.
35. Jain N., Curran E., Iyengar N.M., Diaz-Flores E., Kunnavakkam R., Popplewell L., Kirschbaum M.H., Karrison T., Erba H.P., Green M., Poire X., Koval G., Shannon K., Reddy P.L., Joseph L., Atallah E.L., Dy P., Thomas S.P., Smith S.E., Doyle L.A., Stadler W.M., Larson R.A., Stock W., Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin. Cancer Res. 2014, 20:490-498.
36. Akinleye A., Furqan M., Mukhi N., Ravella P., Liu D. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 2013, 6:27.
37. Daver N., Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology 2012, 17(Suppl. 1):S59-62.
38. Bachegowda L., Gligich O., Mantzaris I., Schinke C., Wyville D., Carrillo T., Braunschweig I., Steidl U., Verma A. Signal transduction inhibitors in treatment of myelodysplastic syndromes. J. Hematol. Oncol. 2013, 6:50.
39. Fremin C., Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 2010, 3:8.
40. Kamakura S., Moriguchi T., Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 1999, 274:26563-26571.
41. Razumovskaya E., Sun J., Ronnstrand L. Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD. Biochem. Biophys. Res. Commun. 2011, 412:307-312.
42. Mody N., Leitch J., Armstrong C., Dixon J., Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett. 2001, 502:21-24.
43. Mazzone A., Ricevuti G. Leukocyte CD11/CD18 integrins: biological and clinical relevance. Haematologica 1995, 80:161-175.
44. Rovera G., O'Brien T.G., Diamond L. Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 1979, 204:868-870.
45. Gutsch R., Kandemir J.D., Pietsch D., Cappello C., Meyer J., Simanowski K., Huber R., Brand K. CCAAT/enhancer-binding protein beta inhibits proliferation in monocytic cells by affecting the retinoblastoma protein/E2F/cyclin E pathway but is not directly required for macrophage morphology. J. Biol. Chem. 2011, 286:22716-22729.
46. Hass R., Prudovsky I., Kruhoffer M. Differential effects of phorbol ester on signaling and gene expression in human leukemia cells. Leuk. Res. 1997, 21:589-594.
47. Nagl M., Kacani L., Mullauer B., Lemberger E.M., Stoiber H., Sprinzl G.M., Schennach H., Dierich M.P. Phagocytosis and killing of bacteria by professional phagocytes and dendritic cells. Clin. Diag. Lab. Immunol. 2002, 9:1165-1168.
48. Fossati-Jimack L., Ling G.S., Cortini A., Szajna M., Malik T.H., McDonald J.U., Pickering M.C., Cook H.T., Taylor P.R., Botto M. Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells. PLoS One 2013, 8:e57082.
49. Schwende H., Fitzke E., Ambs P., Dieter P. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3. J. Leukoc. Biol. 1996, 59:555-561.
50. Collins S.J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987, 70:1233-1244.
51. Studzinski G.P., Bhandal A.K., Brelvi Z.S. A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol. Proc. Soc. Exp. Biol. Med. 1985, 179:288-295.
52. 3-induced differentiation of HL60 cells. J. Cell Biochem. 2001, 80:471-482.
53. Marcinkowska E. Evidence that activation of MEK1,2/erk1,2 signal transduction pathway is necessary for calcitriol-induced differentiation of HL-60 cells. Anticancer Res. 2001, 21:499-504.
54. Grieser C., Heine G., Stelter L., Steffen I.G., Rothe J.H., Walter T.C., Fischer C., Bahra M., Denecke T. Morphological analysis and differentiation of benign cystic neoplasms of the pancreas using computed tomography and magnetic resonance imaging. RöFo - Fortschr. Rontg. 2013, 185:219-227.
55. Grage-Griebenow E., Lorenzen D., Fetting R., Flad H.D., Ernst M. Phenotypical and functional characterization of Fc gamma receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity. Eur. J. Immunol. 1993, 23:3126-3135.
56. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
57. Gordon S. The macrophage: past, present and future. Eur. J. Immunol. 2007, 37(Suppl 1):S9-17.
58. Mitrasinovic O.M., Murphy G.M. Accelerated phagocytosis of amyloid-beta by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor. J. Biol. Chem. 2002, 277:29889-29896.
59. Mitrasinovic O.M., Murphy G.M. Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta. Neurobiol. Aging 2003, 24:807-815.
60. Hoebe E.K., Le Large T.Y., Tarbouriech N., Oosterhoff D., De Gruijl T.D., Middeldorp J.M., Greijer A.E. Epstein-Barr virus-encoded BARF1 protein is a decoy receptor for macrophage colony stimulating factor and interferes with macrophage differentiation and activation. Viral Immunol. 2012, 25:461-470.
61. Shi C., Sakuma M., Mooroka T., Liscoe A., Gao H., Croce K.J., Sharma A., Kaplan D., Greaves D.R., Wang Y., Simon D.I. Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood 2008, 112:4699-4711.
62. Daigneault M., Preston J.A., Marriott H.M., Whyte M.K., Dockrell D.H. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 2010, 5:e8668.
63. Erazo T., Moreno A., Ruiz-Babot G., Rodriguez-Asiain A., Morrice N.A., Espadamala J., Bayascas J.R., Gomez N., Lizcano J.M. Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. Mol. Cell Biol. 2013, 33:1671-1686.